ArticleCardiology and therapy2026

Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy.

Daniel P Judge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.